ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy

BACKGROUND: Ticagrelor, when compared with clopidogrel, reduced the 12-month risk of vascular death/myocardial infarction and stroke in patients with ST-elevation acute coronary syndromes intended to undergo primary percutaneous coronary intervention in the PLATelet inhibition and patient Outcomes (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Armstrong, Paul W. (VerfasserIn) , Katus, Hugo (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2012
In: Circulation
Year: 2011, Jahrgang: 125, Heft: 3, Pages: 514-521
ISSN:1524-4539
DOI:10.1161/CIRCULATIONAHA.111.047530
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1161/CIRCULATIONAHA.111.047530
Volltext
Verfasserangaben:Paul W. Armstrong, Hany Siha, Yuling Fu, Cynthia M. Westerhout, Ph. Gabriel Steg, Stefan K. James, Robert F. Storey, Jay Horrow, Hugo Katus, Peter Clemmensen, Robert A. Harrington, Lars Wallentin

MARC

LEADER 00000caa a2200000 c 4500
001 1578186544
003 DE-627
005 20220814204548.0
007 cr uuu---uuuuu
008 180802r20122011xx |||||o 00| ||eng c
024 7 |a 10.1161/CIRCULATIONAHA.111.047530  |2 doi 
035 |a (DE-627)1578186544 
035 |a (DE-576)508186544 
035 |a (DE-599)BSZ508186544 
035 |a (OCoLC)1341016056 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Armstrong, Paul W.  |e VerfasserIn  |0 (DE-588)1163745677  |0 (DE-627)1028107315  |0 (DE-576)508189055  |4 aut 
245 1 0 |a ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial  |b insights from the ECG substudy  |c Paul W. Armstrong, Hany Siha, Yuling Fu, Cynthia M. Westerhout, Ph. Gabriel Steg, Stefan K. James, Robert F. Storey, Jay Horrow, Hugo Katus, Peter Clemmensen, Robert A. Harrington, Lars Wallentin 
264 1 |c 2012 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Originally published 16 December 2011 
500 |a Gesehen am 02.08.2018 
520 |a BACKGROUND: Ticagrelor, when compared with clopidogrel, reduced the 12-month risk of vascular death/myocardial infarction and stroke in patients with ST-elevation acute coronary syndromes intended to undergo primary percutaneous coronary intervention in the PLATelet inhibition and patient Outcomes (PLATO) trial. This prespecified ECG substudy explored whether ticagrelor's association with vascular death and myocardial infarction within 1 year would be amplified by (1) the extent of baseline ST shift and (2) subsequently associated with fewer residual ST changes at hospital discharge. METHODS AND RESULTS: ECGs were evaluated centrally in a core laboratory in 3122 ticagrelor- and 3084 clopidogrel-assigned patients having at least 1 mm ST-elevation in 2 contiguous leads as identified by site investigators on the qualifying ECG. Patients with greater ST-segment shift at baseline had higher rates of vascular death/myocardial infarction within 1 year. Among those who also had an ECG at hospital discharge (n=4798), patients with ≥50% ΣST-deviation (ΣST-dev) resolution had higher event-free survival than those with incomplete resolution (6.4% versus 8.8%, adjusted hazard ratio 0.69 (0.54-0.88), P=0.003). The extent of ΣST-dev resolution was similar irrespective of treatment assignment. The benefit of ticagrelor versus clopidogrel on clinical events was consistent irrespective of the extent of baseline ΣST-dev (P(interaction)=0.728). When stratified according to conventional times from symptom onset, ie, ≤3 hours, 3 to 6 hours, >6 hours, the extent of baseline ΣST-dev declined progressively over time. As time from symptom onset increased beyond 3 hours, the benefit of ticagrelor appeared to be more pronounced; however, the interaction between time and treatment was not significant (P=0.175). CONCLUSIONS: Ticagrelor did not modify ΣST-dev resolution at discharge nor was its benefit affected by the extent of baseline ΣST-dev. These hypothesis-generating observations suggest that the main effects of ticagrelor may not relate to the rapidity or the completeness of acute reperfusion, but rather the prevention of recurrent vascular events by more powerful platelet inhibition or other mechanisms. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872. 
534 |c 2011 
650 4 |a Acute Coronary Syndrome 
650 4 |a Adenosine 
650 4 |a Aged 
650 4 |a Angioplasty, Balloon, Coronary 
650 4 |a Electrocardiography 
650 4 |a Female 
650 4 |a Humans 
650 4 |a Kaplan-Meier Estimate 
650 4 |a Male 
650 4 |a Middle Aged 
650 4 |a Myocardial Infarction 
650 4 |a Platelet Aggregation Inhibitors 
650 4 |a Purinergic P2Y Receptor Antagonists 
650 4 |a Risk Factors 
650 4 |a Ticlopidine 
700 1 |a Katus, Hugo  |d 1951-  |e VerfasserIn  |0 (DE-588)108916618  |0 (DE-627)577155040  |0 (DE-576)289625076  |4 aut 
773 0 8 |i Enthalten in  |t Circulation  |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950  |g 125(2012), 3, Seite 514-521  |h Online-Ressource  |w (DE-627)265784670  |w (DE-600)1466401-X  |w (DE-576)074891189  |x 1524-4539  |7 nnas  |a ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial insights from the ECG substudy 
773 1 8 |g volume:125  |g year:2012  |g number:3  |g pages:514-521  |g extent:8  |a ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial insights from the ECG substudy 
856 4 0 |u http://dx.doi.org/10.1161/CIRCULATIONAHA.111.047530  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180802 
993 |a Article 
994 |a 2012 
998 |g 108916618  |a Katus, Hugo  |m 108916618:Katus, Hugo  |d 910000  |d 910100  |e 910000PK108916618  |e 910100PK108916618  |k 0/910000/  |k 1/910000/910100/  |p 9 
999 |a KXP-PPN1578186544  |e 3020077850 
BIB |a Y 
SER |a newspaper 
JSO |a {"person":[{"role":"aut","family":"Armstrong","display":"Armstrong, Paul W.","given":"Paul W."},{"role":"aut","family":"Katus","given":"Hugo","display":"Katus, Hugo"}],"recId":"1578186544","note":["Originally published 16 December 2011","Gesehen am 02.08.2018"],"name":{"displayForm":["Paul W. Armstrong, Hany Siha, Yuling Fu, Cynthia M. Westerhout, Ph. Gabriel Steg, Stefan K. James, Robert F. Storey, Jay Horrow, Hugo Katus, Peter Clemmensen, Robert A. Harrington, Lars Wallentin"]},"language":["eng"],"relHost":[{"corporate":[{"role":"isb","display":"American Heart Association"}],"disp":"ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial insights from the ECG substudyCirculation","type":{"bibl":"newspaper","media":"Online-Ressource"},"pubHistory":["1.1950 -"],"note":["Gesehen am 10.10.2025"],"language":["eng"],"part":{"extent":"8","pages":"514-521","issue":"3","text":"125(2012), 3, Seite 514-521","volume":"125","year":"2012"},"origin":[{"dateIssuedDisp":"1950-","publisher":"Lippincott, Williams & Wilkins ; Ovid","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1950"}],"title":[{"title_sort":"Circulation","subtitle":"an official journal of the American Heart Association","title":"Circulation"}],"id":{"issn":["1524-4539"],"eki":["265784670"],"zdb":["1466401-X"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"265784670"}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"title":[{"subtitle":"insights from the ECG substudy","title":"ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial","title_sort":"ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial"}],"type":{"bibl":"article-newspaper","media":"Online-Ressource"},"physDesc":[{"extent":"8 S."}],"id":{"eki":["1578186544"],"doi":["10.1161/CIRCULATIONAHA.111.047530"]}} 
SRT |a ARMSTRONGPSTELEVATIO2012